These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 39195270)

  • 1. Molecular Susceptibility and Treatment Challenges in Melanoma.
    Kolathur KK; Nag R; Shenoy PV; Malik Y; Varanasi SM; Angom RS; Mukhopadhyay D
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced Melanoma: Resistance Mechanisms to Current Therapies.
    Haugh AM; Salama AKS; Johnson DB
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):111-128. PubMed ID: 33759769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
    Dulgar O; Kutuk T; Eroglu Z
    Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors.
    Motti ML; Minopoli M; Di Carluccio G; Ascierto PA; Carriero MV
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.
    Fukumoto T; Lin J; Fatkhutdinov N; Liu P; Somasundaram R; Herlyn M; Zhang R; Nishigori C
    J Invest Dermatol; 2021 Jun; 141(6):1564-1572.e4. PubMed ID: 33333124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma.
    Nguyen MT; Luo YH; Li AL; Tsai JC; Wu KL; Chung PJ; Ma N
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
    Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
    Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells.
    Liu M; Zhao Z; Wang C; Sang S; Cui Y; Lv C; Yang X; Zhang N; Xiong K; Chen B; Dong Q; Liu K; Gu Y
    Cancer Lett; 2024 Jul; 594():216991. PubMed ID: 38797232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic progression of malignant melanoma.
    Tímár J; Vizkeleti L; Doma V; Barbai T; Rásó E
    Cancer Metastasis Rev; 2016 Mar; 35(1):93-107. PubMed ID: 26970965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
    Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
    J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
    Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
    Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
    Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
    Front Immunol; 2021; 12():798474. PubMed ID: 35087523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
    Olbryt M; Rajczykowski M; Widłak W
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.
    Wen X; Han M; Hosoya M; Toshima R; Onishi M; Fujii T; Yamaguchi S; Kato S
    Anticancer Res; 2024 Jun; 44(6):2349-2358. PubMed ID: 38821628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.
    Johnson DB; Menzies AM; Zimmer L; Eroglu Z; Ye F; Zhao S; Rizos H; Sucker A; Scolyer RA; Gutzmer R; Gogas H; Kefford RF; Thompson JF; Becker JC; Berking C; Egberts F; Loquai C; Goldinger SM; Pupo GM; Hugo W; Kong X; Garraway LA; Sosman JA; Ribas A; Lo RS; Long GV; Schadendorf D
    Eur J Cancer; 2015 Dec; 51(18):2792-9. PubMed ID: 26608120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
    Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
    Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
    Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
    Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
    Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
    Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.